2020-03-16 |
11 |
Answer to Complaint |
U.S. Patent Nos. 7,888,362 (“’362 patent”), 8,349,840 (“’840 patent”),
8,618,109 (’109 patent”), 9,839,637… U.S. Patent Nos. 7,888,362
(“’362 patent”), 8,349,840 (“’840 patent”), 8,618,109 (“’109 patent”), 9,…civil action for patent infringement of U.S. Patent Nos. 7,888,362 (“the
’362 patent”), 8,349,840 (“the…the ’840 patent”), 8,618,109 (“the ’109 patent”), 9,839,637 (“the ’637
patent”), and 10,307,419 (“the …the ’419 patent”) (collectively, “patents in suit”), arising under the
United States patent laws, Title |
External link to document |
2020-09-30 |
18 |
Status Report |
of those patents, U.S. Patent No.
10,307,419 (“the ’419 patent”), is a formulation patent directed to…8,349,840; 8,618,109;
9,839,637 and 10,307,419 (“the ’419 patent”), which cover brexpiprazole, its use…allegations of patent infringement.
Plaintiffs have asserted five patents-in-suit: U.S. Patent Nos. 7,888,362…other four patents. The ’419 patent expires over six years later than the
other four patents.
…This is an action for patent infringement of Otsuka Pharmaceutical Co., Ltd.’s patents
covering REXULTI® |
External link to document |
2019-11-01 |
4 |
Patent/Trademark Report to Commissioner of Patents |
the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,888,362 ;8,349,840 ;8,618,109…2019
31 August 2022
1:19-cv-02080
835 Patent - Abbreviated New Drug Application(ANDA)
Defendant |
External link to document |